1,080 results on '"Kastelein, John J.P."'
Search Results
2. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials
3. Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
4. The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
5. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
6. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
7. Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model
8. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
9. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
10. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study
11. Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic
12. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
13. Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
14. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
15. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4
16. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
17. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
18. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
19. Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
20. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
21. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
22. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
23. Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study.
24. Effect of Evolocumab on Coronary Plaque Composition
25. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
26. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
27. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
28. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
29. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
30. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
31. CETP and SGLT2 inhibitor combination therapy improves glycemic control
32. Pegozafermin for the Treatment of Severe Hypertriglyceridemia: A Randomized, Double-blind, Placebo-controlled Phase 2 Study (ENTRIGUE STUDY)
33. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia
34. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial
35. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
36. CETP and SGLT2 inhibitor combination therapy improves glycemic control
37. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
38. PEGOZAFERMIN PROVIDES BENEFICIAL LIPID EFFECTS IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA REGARDLESS OF BACKGROUND LIPID MODIFYING THERAPY STATUS: AN ANALYSIS OF THE PHASE 2 ENTRIGUE STUDY
39. Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment
40. Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment
41. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
42. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)
43. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
44. Children with hypercholesterolemia of unknown cause: Value of genetic risk scores
45. Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution
46. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
47. Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia
48. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial
49. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS
50. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.